Alkeus Pharmaceuticals’ study results from Gildeuretinol shows significant trend in slowing geographic atrophy: Cambridge, Massachusetts Friday, October 25, 2024, 10:00 Hrs [IST ...

Pharmaceuticals announced that the first patient has been dosed in the Phase 3 LUGANO clinical trial of DURAVYU, formerly ...

Preliminary data from a late stage clinical trial of a retinal implant showed promising results, Science Corporation said ...

Nutritional supplements that contain curcumin -- a natural anti-inflammatory compound -- may protect the eyes from the ...

Dr Arshad Khanani anticipates presentations offering new strategies to tackle challenges such as macular atrophy and fibrosis, and optimizing dosing intervals in wet AMD.

Light therapy could be a useful treatment for the most common form of age-related macular degeneration, a new study says.

The fight against Age Related Molecular Degeneration Market is seeing a promising boost. According to a recent analysis, the ...

Data about higher doses that are injected less often come as the original 2-milligram dose of Eylea is facing an increasing ...

Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study ...

OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of ...

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet ...

What treatments are available to treat vision loss ... and it may not lead to total blindness. But with wet macular degeneration, symptoms progress rapidly–sometimes within a couple of weeks. What is ...